← NMN

NAD+ Precursor and Longevity

How nicotinamide mononucleotide boosts NAD+ levels, supports mitochondrial energy, insulin sensitivity, and healthy aging — and what the human trials show

NMN (nicotinamide mononucleotide) is a molecule your body naturally produces and uses to make NAD+ — a coenzyme that every cell needs to generate energy, repair DNA, and regulate hundreds of enzymes. NAD+ levels fall by roughly half between your twenties and fifties, and this decline is increasingly linked to the metabolic and cellular changes associated with aging [6]. By supplying NMN directly, you give your body a ready building block to replenish NAD+ without the bottlenecks that slow other pathways. Early human clinical trials confirm that NMN raises blood NAD+ metabolites [1], improves muscle insulin sensitivity [2], and supports physical performance in middle age [4] — all with a clean safety profile [3].

How NMN Works

NAD+ (nicotinamide adenine dinucleotide) is one of the most fundamental molecules in biology. It sits at the center of metabolism, shuttling electrons during energy production, activating sirtuins (enzymes that regulate cellular repair and longevity), and fueling PARP enzymes that fix DNA damage after oxidative stress or UV exposure [6].

Your body makes NAD+ through several pathways. The main one — the salvage pathway — starts with nicotinamide (a form of vitamin B3) and converts it through a series of steps into NAD+. NMN slots into this pathway one step ahead of NAD+ itself, bypassing some of the rate-limiting steps that can slow conversion. Once absorbed, NMN enters cells via a dedicated transporter (Slc12a8 in rodents, with evidence of analogous transport in human intestinal tissue) and is rapidly converted to NAD+ inside [6].

The NAD+ decline with age is not subtle. Studies in humans and animals show that NAD+ levels in muscle, liver, and skin fall by 40–60% between young adulthood and middle age, correlating with declines in mitochondrial function, insulin sensitivity, and DNA repair capacity [2]. This decline appears to result from both slower NAD+ synthesis and faster consumption by inflammatory enzymes (CD38) that accumulate with age and chronic inflammation.

What the Science Shows

Energy and metabolism. NAD+ is essential for mitochondrial function. As levels fall, mitochondria produce ATP less efficiently — one reason older adults experience fatigue and reduced exercise tolerance. Restoring NAD+ with NMN in aging animal models reliably improved mitochondrial function, and human trials now show blood NAD+ metabolite increases after oral supplementation [1][7].

Insulin sensitivity. A landmark 2021 trial published in Science found that 250 mg/day NMN for 10 weeks significantly increased skeletal muscle insulin sensitivity in postmenopausal women with prediabetes — measured via hyperinsulinemic-euglycemic clamp, the gold standard method [2]. Muscle gene expression analysis showed upregulation of pathways involved in glucose uptake and insulin signaling. This is the most rigorous human metabolic NMN trial to date.

Physical performance. A dose-finding trial in healthy middle-aged adults (40–65 years) found that 600 mg/day NMN for 60 days improved muscle strength and performance measures compared to placebo, with a dose-response pattern where 600 mg/day outperformed both lower and higher doses [4]. A separate trial in older adults with diabetes and physical impairment found improvements in grip strength and walking speed with 250 mg/day NMN over 12 weeks [5].

Sleep and metabolism. A 12-week trial in healthy middle-aged men found that long-term NMN supplementation improved sleep quality scores alongside NAD+ metabolite elevation, and was associated with beneficial changes in blood glucose and lipid metabolism [7].

NMN vs. NR: Which NAD+ Precursor?

NMN is closely related to NR (nicotinamide riboside), another popular NAD+ precursor. NR is converted to NMN in cells before being used to make NAD+. Both raise NAD+ levels effectively in humans, but they differ in:

Size. NMN is slightly larger. Some research suggested NMN might not survive the intestine intact, but newer studies confirm oral NMN does raise blood NAD+ metabolites, likely via intestinal transport mechanisms [1][6].
Cost. NR supplements are generally less expensive.
Bioavailability. A direct head-to-head comparison in humans is still lacking. Both appear effective at raising blood NAD+ metabolites in clinical trials.
Research depth. NR has a somewhat larger body of published human trials, though high-quality NMN trials have accelerated since 2021.

For most people, either precursor is a reasonable choice. NMN may have advantages in tissues expressing the Slc12a8-type transporter, while NR's smaller size may confer advantages in other tissues [6].

Dosage and Practical Use

Human trials have used 250–1,250 mg/day. The most studied range for metabolic and performance effects is 250–600 mg/day. The 2023 dose-finding trial identified 600 mg/day as the apparent sweet spot for physical performance outcomes in middle-aged adults [4]. Safety testing at doses up to 1,250 mg/day for 4 weeks found no serious adverse effects, with blood chemistry and vitals remaining normal [3].

NMN is generally taken in the morning, since NAD+ is involved in circadian signaling. Taking it with or without food appears equivalent based on current data. Most capsule and sublingual forms have demonstrated efficacy in trials.

NMN is a food compound found in small amounts in edamame, broccoli, cucumber, avocado, and tomatoes — but dietary intake is far too low (nanograms to micrograms) to meaningfully raise blood NAD+ levels. Supplementation is the only practical way to deliver gram-range doses.

See our CoQ10 page and mitochondrial health page for related approaches to cellular energy.

Evidence Review

First Human NMN Dosing Study (Irie et al., 2020)

The first-in-human oral NMN study administered single doses of 100, 250, or 500 mg NMN to 10 healthy Japanese men and monitored safety and NAD+ metabolite changes for 5 hours post-dose [1]. No adverse changes were seen in vital signs, blood glucose, oxygen saturation, body temperature, or 44 blood chemistry markers across all doses. Urinary and blood NAD+ metabolites (NAM, NAAD, MeNAM, MeNAM, NMN itself) rose dose-dependently, confirming that oral NMN is absorbed and metabolically active in humans. This established the foundational safety and pharmacokinetic profile for human NMN trials. Limitations: single-dose design, all-male cohort, small sample size (n=10), no placebo comparison.

Muscle Insulin Sensitivity RCT (Yoshino et al., 2021)

Published in Science, this 10-week double-blind RCT enrolled 25 postmenopausal women with prediabetes (BMI 25–40, impaired fasting glucose) [2]. Thirteen received 250 mg/day NMN and 12 received placebo. Muscle insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp with stable isotope tracer — the most rigorous available method. NMN significantly increased skeletal muscle insulin-stimulated glucose disposal (Rd; 1.4-fold, p<0.05) compared to placebo. Skeletal muscle RNA sequencing revealed that NMN upregulated expression of genes involved in muscle remodeling and glucose metabolism, particularly SIRT1 and insulin signaling pathways. Blood NAD+ metabolites rose significantly. No changes in body weight, adiposity, blood pressure, or adverse events were observed. Key limitation: 250 mg/day is a low dose; larger trials with higher doses are needed. This remains the highest-quality metabolic NMN trial in humans.

Safety RCT (Fukamizu et al., 2022)

This 12-week, randomized, double-blind, placebo-controlled trial tested 250 or 500 mg/day NMN in 31 healthy adult men and women (40–65 years) [3]. A separate single-dose arm tested up to 1,250 mg. Safety outcomes included 117 blood chemistry parameters, electrocardiography, ophthalmology, vital signs, and adverse event reporting. No serious adverse events occurred at any dose. Mild, transient events (headache, fatigue) were equally distributed between NMN and placebo groups. All laboratory values remained within normal reference ranges. Blood and urine NMN and NAD+ metabolites rose dose-dependently. This is the most comprehensive safety profile published for oral NMN in humans to date, providing confidence for doses up to at least 1,250 mg as a single dose and 500 mg/day as a chronic dose.

Dose-Finding Physical Performance RCT (Yi et al., 2023)

This multicenter, double-blind, placebo-controlled trial enrolled 80 healthy adults aged 40–65 years across four groups: placebo, 300, 600, or 900 mg/day NMN for 60 days [4]. Primary outcomes were NAD+ metabolite levels; secondary outcomes included physical performance tests (grip strength, timed-up-and-go, 6-minute walk test) and subjective fatigue. Blood NAD+ metabolites rose significantly in all NMN groups versus placebo. On physical performance measures, the 600 mg/day group showed the most consistent improvements, outperforming both 300 mg and 900 mg groups — suggesting a U-shaped dose-response. The 900 mg group showed no additional benefit, possibly due to metabolic saturation or feedback regulation. Grip strength improvements reached statistical significance at 600 mg (p<0.05). No serious adverse events occurred. Limitation: 60 days may be too short to observe the full range of NAD+-mediated effects.

Older Adults with Diabetes (Akasaka et al., 2023)

This prospective, double-blind, placebo-controlled trial enrolled 30 older adults (mean age ~70) with type 2 diabetes and impaired physical performance (Short Physical Performance Battery score ≤9) [5]. Participants received 250 mg/day NMN or placebo for 12 weeks on top of standard diabetes care. The NMN group showed significantly greater improvements in grip strength (p<0.05) and SPPB total score (p<0.05) compared to placebo. Blood NAD+ metabolites rose significantly in the NMN group. HbA1c and fasting glucose showed a trend toward improvement that did not reach significance at this sample size (n=30). No serious adverse events occurred. This trial is notable for demonstrating benefits specifically in an older, clinically relevant population — the demographic most likely to be NAD+-depleted and most in need of functional interventions.

NMN vs. NR Comparative Review (Soares Alegre & Pastore, 2023)

This narrative review compared the evidence base, metabolic pathways, and bioavailability of NMN and NR as NAD+ precursors [6]. Key findings: both precursors reliably raise blood NAD+ metabolites in published human trials. NMN is one step closer to NAD+ in the biosynthetic pathway, which may confer advantages in tissues with active Slc12a8-type transporters. NR must first be converted to NMN before NAD+ synthesis. Dietary sources of NMN exist (edamame ~1.88 mg/100g, broccoli ~0.25–1.12 mg/100g) but are pharmacologically negligible. The review notes that the clinical evidence base for both precursors is growing rapidly but remains limited in scale and duration, with most trials spanning 8–12 weeks and fewer than 100 participants. Head-to-head comparative trials in humans are lacking, making definitive claims about superiority premature.

Long-Term Safety and Metabolism (Yamaguchi et al., 2024)

This 12-week open-label extension study followed 10 healthy middle-aged Japanese men receiving 250 mg/day NMN continuously [7]. Primary outcomes were safety (extended blood chemistry panel, adverse events) and metabolic parameters including blood glucose, lipids, liver enzymes, and sleep quality. Blood NAD+ metabolites remained elevated throughout the 12-week period. Sleep quality scores (Pittsburgh Sleep Quality Index) improved significantly from baseline (p<0.05). Fasting blood glucose and HbA1c showed modest improvements not reaching statistical significance. All safety parameters remained normal throughout. This is the longest continuous human NMN dosing study published to date, though the small sample size (n=10) and lack of a parallel placebo arm limit interpretation. It provides useful preliminary evidence that metabolic benefits and safety profile are maintained with extended supplementation.

Overall Evidence Assessment

The human evidence for NMN is promising but early. The strongest data supports: (1) oral NMN reliably raises blood NAD+ metabolites in a dose-dependent manner; (2) doses up to 1,250 mg are safe with no serious adverse events across multiple trials; (3) 250 mg/day improves muscle insulin sensitivity in prediabetic women (single well-powered trial); (4) 600 mg/day improves physical performance measures in middle-aged adults (one multicenter trial). What remains unclear: long-term effects beyond 12 weeks, optimal dosing for specific health goals, and whether NAD+ restoration translates to meaningful reductions in age-related disease. The field is moving quickly — several larger trials are underway. Current evidence is sufficient to support cautious use in middle-aged to older adults seeking to support metabolic and mitochondrial health, while acknowledging this is an emerging area rather than a fully established intervention.

References

Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese menIrie J, Inagaki E, Fujita M, Nakaya H, Mitsuishi M, Yamaguchi S, Yamashita K, Shigaki S, Ono T, Yukioka H, Okano H, Nabeshima YI, Imai SI, Yasui M, Tsubota K, Itoh H. Endocrine Journal, 2020. PubMed 31685720 →
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenYoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Science, 2021. PubMed 33888596 →
Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and womenFukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T. Scientific Reports, 2022. PubMed 36002548 →
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trialYi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. Geroscience, 2023. PubMed 36482258 →
Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind studyAkasaka H, Nakagami H, Sugimoto K, Yasunobe Y, Minami T, Fujimoto T, Yamamoto K, Hara C, Shiraki A, Nishida K, Asano K, Kanou M, Yamana K, Imai SI, Rakugi H. Geriatrics & Gerontology International, 2023. PubMed 36443648 →
NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to HealthSoares Alegre GF, Pastore GM. Current Nutrition Reports, 2023. PubMed 37273100 →
Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese menYamaguchi S, Irie J, Mitsuishi M, Uchino Y, Nakaya H, Takemura R, Inagaki E, Kosugi S, Okano H, Yasui M, Tsubota K, Hayashi K, Yoshino J, Itoh H. Endocrine Journal, 2024. PubMed 38191197 →